Timothy A. Yap, Alberto Hernando Hernando-Calvo, Emiliano Calvo, Víctor Moreno, Raul Marquez, Kyriakos P. Papadopoulos, Javier Garcia García - Corbacho, Tatiana Hernandez Guerrero, Alexander I. Spira, David Shao Peng Tan, Christian H.H Ottensmeier, Secil Koseoglu, Philip K Chang, Eddie Zhang, Jorge Luis Martinez, Christina Trück, Rita Magenheim, Ilhan Celik, Özlem Türeci, Uğur Şahin. "First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.2501